Ascendis Pharma A (ASND) Return on Sales (2014 - 2026)

Ascendis Pharma A has disclosed Return on Sales across 13 years of filings, most recently posting 0.03% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.03%, up 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 1.0% YoY), and the FY2025 annual result was 0.0%, up 1.0% from the prior year.
• Return on Sales came in at 0.03% for Q1 2026 at Ascendis Pharma A, up from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q1 2026 to a low of 0.18% in Q1 2022.
• The 5-year median for Return on Sales is 0.02% (2024), against an average of 0.04%.
• Peak annual rise in Return on Sales reached 118 bps in 2022, while the deepest fall reached 7 bps in 2022.
• Ascendis Pharma A's Return on Sales stood at 0.09% in 2022, then soared by 96 bps to 0.0% in 2023, then jumped by 54 bps to 0.0% in 2024, then soared by 58 bps to 0.0% in 2025, then soared by 4301 bps to 0.03% in 2026.
• The last three Return on Sales figures came in at 0.03% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.